A Phase 1, Single-Dose, Open-Label Trial to Evaluate the Pharmacokinetics and Safety of AG-120 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects

Trial Profile

A Phase 1, Single-Dose, Open-Label Trial to Evaluate the Pharmacokinetics and Safety of AG-120 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Acute myeloid leukaemia; Cholangiocarcinoma; Glioma; Myelodysplastic syndromes; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top